At Sol-Gel, we’re committed to elevating treatment paradigms by developing breakthrough solutions for rare skin conditions.

Apr 4, 2025 · Sol-Gel was successful in developing pioneer topical drugs, Twyneo® and Epsolay®, for the treatment of acne and inflammatory lesions of rosacea. Both products are marketed in the US by Galderma since 2022.

Sol-Gel Technologies announces FDA approval of TWYNEO®. Sol-gel.com. July 27, 2021. Accessed August 22, 2023. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor.

Sep 30, 2024 · Sol-Gel reported a net loss of $0.4 million for the third quarter of 2024 and loss of $0.01 per basic and diluted share, compared to a net loss of $5.7 million and a loss of $0.21 per basic and diluted share for the same period in 2023.

Jul 27, 2021 · Sol‑Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is approved for the treatment of acne vulgaris in adults and pediatric patients 9 years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was ...

May 16, 2024 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.

Sol-Gel Technologies is an experienced dermatology company that is leveraging innovative approaches to develop advanced treatments for patients with severe skin conditions.

Sol-Gel is seeking to expand its pipeline of dermatological drug products by acquiring proven drug candidates. We are also open to opportunities to license out our proprietary assets. For partnership inquiries, please send us a message on our Contact page.

Gorlin syndrome, also known as nevoid basal cell carcinoma (BCC), is a rare genetic skin disorder that can affect nearly every organ system in the body. 1 People living with Gorlin syndrome are at increased risk of developing BCC skin cancers, which are the most common manifestation of the disorder. Gorlin syndrome affects an estimated 1 in 31,000 people. 2

Jul 12, 2024 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.